Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Phase II, Prospective Study of Transcatheter Arterial Chemoembolization, Lenvatinib Combination With Sintilimab Sequential Radiotherapy in Patients With Initial Unresectable Hepatocellular Carcinoma

NCT06561399 is registered in ClinicalTrials.gov with Fujian Provincial Hospital as lead sponsor.

NCT NCT06561399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06561399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Phase II, Prospective Study of Transcatheter Arterial Chemoembolization, Lenvatinib Combination With Sintilimab Sequential Radiotherapy in Patients With Initial Unresectable Hepatocellular Carcinoma
Lead sponsor
Fujian Provincial Hospital
Phase
Observational
Overall status
Recruiting
Start date
August 15, 2024
Completion date
July 1, 2028
Enrollment
28 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma non-resectable